Abeona Therapeutics (NASDAQ: ABEO) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Abeona Therapeutics to related companies based on the strength of its profitability, valuation, analyst recommendations, dividends, earnings, institutional ownership and risk.
This table compares Abeona Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Abeona Therapeutics Competitors||-3,984.80%||-117.96%||-44.22%|
Volatility and Risk
Abeona Therapeutics has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Abeona Therapeutics’ peers have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.
This is a summary of recent ratings and price targets for Abeona Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Abeona Therapeutics Competitors||474||2249||6143||119||2.66|
Abeona Therapeutics presently has a consensus target price of $24.13, indicating a potential upside of 44.46%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.41%. Given Abeona Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Abeona Therapeutics is more favorable than its peers.
Earnings and Valuation
This table compares Abeona Therapeutics and its peers revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Abeona Therapeutics||$842,999.00||-$23.80 million||-27.38|
|Abeona Therapeutics Competitors||$207.78 million||-$2.31 million||0.51|
Abeona Therapeutics’ peers have higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
38.4% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.8% of Abeona Therapeutics shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Abeona Therapeutics beats its peers on 7 of the 12 factors compared.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.